Figure 3.

Time from the first description of an ADR in the SmPC of any of the TNF‐α inhibitors to the first description of the same ADR in the SmPC of a second TNF‐α inhibitor. ADR, adverse drug reactions; SmPC, summary of product characteristic. [Colour figure can be viewed at wileyonlinelibrary.com]